Bibliography:
1. Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and projected estimate for people with cystic fibrosis using baseline characteristics: a longitudinal study using UK patient registry data. J Cyst Fibros 2018; 17: 218-227. 2. Stephenson AL, Tom M, Berthiaume Y, Singer LG, Aaron SD, Whitmore GA, Stanojevic S. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Resp J 2015; 45: 670-679.
3. MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH, Marshall BC. Longevity of patients with cystic fibrosis in 2000-2010 and beyond: survival analysis of the Cystic Fibrosis Foundation Patient Registry. Ann Intern Med 2014: 161: 233-241.
4. Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Hoffman G, Laessig R, Rock MJ, Splaingard ML. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! J Pediatr 2005; 147: S30-36. 5. Tridello G, Castellini C, Menegheilli I, Tamanini A, Assael BM. Early diagnosis from newborn screening maximizes survival in severe cystic fibrosis. ERJ Open Res 2017: 20; 4:00109-2017. doi: 10.1183/23120541.00109-2017.
6. Sanders DB, Zhang Z, Farrell PM, Lai HJ. Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis. J Cyst Fibros 2018; 17: 528-535.
7. Morgan WJ, Wagener JS, Pasta DJ, Millar SJ, VanDeventer DR, Konstan MW. Relationship of antibiotic treatment to recovery after acute FEV1 decline in children with cystic fibrosis. Ann Am Thorac Soc 2017; 6: 937-942.
8. Middleton PG, Mall MA, Drevinek P, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele. N Engl J Med 2019; 381: 1809-19.
9. Hayes D, Cherikh WS. Chamber DC, Harhay MO, Khush KK, Lehman RR, Meiser B, Rossano JW, Hsich E, Potena L, Sadavarte A, Singh TP, Zuckermann A, Stehlik J. The international Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: twenty-second pediatric lung and heart-lung transplantation report – 2019: focus theme: donor and recipient size match. J Heart Lung Transplant 2019: 38: 105-1027.
10. Ramos KJ, Smith PJ, McKone EF, et al. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros 2019; 18: 321-333.
11. Luna RA, Millecker LA, Webb R, Mason SK, Whaley EM, Starke JR, Hiatt PW, Versalovic J. Molecular epidemiological suveiilance of multi-drug resistant Pseudomonas aeruginosa isolates in a pediatric population of patients with cystic fibrosis and determination of risk factors for infection with the Houston-1 strain. J Clin Microbiol 2013: 51: 1237-1240.
12. Tracy MC, Moss RB. The myriad challenges of respiratory fungal infection in cystic fibrosis. Pediatr Pulmonol 2018; 53: S75-S85.
13. Stern RC, Boat TF, Orenstein DM, Wood RE, Matthews LW, Doerschuk CF. Treatment and prognosis of lobar and segmental atelecatasis in cystic fibrosis. Am Rev Respir Dis 1978; 118: 821-826.
14. Marmon L, Schidlow D, Palmer J, Balsara RK, Dunn JM. Pulmonary resection for complications of cystic fibrosis. J Pediatr Surg 1983; 18: 811-815.
15. Flight WG, Hildage J, Webb AK. Progressive unilateral lung collapse in cystic fibrosis – a therapeutic challenge. J R Soc Med 2012; 105: S44-S49.
16. Perrem L, Stanojevic S, Solomon M, Carpenter S, Ratjen F. Incidence and risk factors of paediatric cystic fibrosis-related diabetes. J Cyst Fibros 2019; 18: 874-878.
17. Moran A, Dunitz J, Nathan B, Saeed A, Home B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes care 2009; 32: 1626-1631.
18. Sanders DB, Slaven JE, Maguiness K, Chmiel JF, Ren CL. Early-life height attainment in cystic fibrosis is associated with pulmonary function at age 6 years. Ann Am Thorac Soc 2021: 18: DOI: 10.1513/AnnalsATS.202008-933OC.
19. Vanderheist E, De Meirleir L, Verbanck S, Pierard D, Vincken W, Malfroot A. Prevalence and impact of FEV1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis: a single-center case control study of 165 patients. J Cyst Fibros 2021; 11: 2-7.
20. McColley SA, Schechter MS, Morgan WJ, Pasta DJ, Craib ML, Konstan MW. Risk factors for mortality before age 18 years in cystic fibrosis. Pediatr Pulmonol 2017; 52: 909-15.
21. Aurora P, Wade A, Whitmore P, Whitehead B. A model for predicting life expectancy of children with cystic fibrosis. Eur Resp J 2000; 16: 1056-1060.
22. VanDeventer DR, Kahle JS, O’Sullivan AK, Sikirica S. Hodgkins PS. Cystic fibrosis in young children: a review of disease manifestation, progression, and response to early treatment. J Cyst Fibros 2016; 15: 147-157.
23. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Robinson KA, Sabadosa KA, Stecenko A, Slovis B. Clinical care guidelines for cystic fibrosis-related diabetes. Diabetes Care 2010; 33: 2697-2708.
24. Schechter MS, Margolis PA. Relationship between socioeconomic status and disease severity in cystic fibrosis. J Pediatr 1998; 132: 260-264.
25. Schechter MS. Nongenetic influences on cystic fibrosis outcomes. Curr Opin Pulm Med 2011; 17: 448-454.
26. Ong T, Schechter M, Yang J, Peng L, et al. Socioeconomic status, smoke exposure and health outcomes in young children with cystic fibrosis. Pediatrics. 2017; 139:e20162730
27. Mehta P, Steinberg EA, Kelly SL, Buchanan C, Rawlinson AR. Medication adherence among adolescent solid-organ transplant recipients: a survey of healthcare providers. Pediatr Transplant 2017; 21: doi: 10.1111/petr.13018.
28. Killian MO, Schuman DL, Mayersohn GS, Triplett KN. Psychosocial predictors of medication non-adherence in pediatric organ transplantation: a systematic review. Pediatr Transplant 2018; 22: e13188.